Common Amino Acid Reverses Liver Damage in Groundbreaking Study

A new study has uncovered a potential treatment for fatty liver disease using a common amino acid. Researchers found that L-aspartate can reverse liver damage caused by poor diet and metabolic stress. The discovery, published in Experimental & Molecular Medicine, offers hope for managing a condition affecting millions worldwide.

The work was led by scientists Cao, Su, and Fu, who identified how L-aspartate blocks harmful interactions between blood cells and liver tissue. Their findings suggest a simple nutritional approach could help combat metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, metabolic dysfunction-associated steatohepatitis (MASH).

The team tested L-aspartate on mice fed a high-fat, high-fructose diet—a model often used to mimic human metabolic disease. In these animals, the supplement reversed key markers of both MASLD and MASH, restoring liver health. Unlike other amino acids or metabolic aids, L-aspartate proved uniquely effective due to its targeted action on cellular pathways.

At the heart of the discovery lies the protein NEK7, which acts as a bridge between signals from platelets and the liver's internal energy systems. When mice consumed unhealthy diets, their platelets became overactive, triggering mitochondrial damage in liver cells. L-aspartate interrupted this process by blocking the ATP-P2X7-NEK7-DRP1 signalling chain, stopping fragmentation and allowing the liver to repair itself.

The research also sheds light on the broader link between blood cell behaviour and metabolic health, a field known as immunometabolism. Platelets, typically associated with clotting, were shown to directly influence liver function under stress. Crucially, L-aspartate's precision in targeting platelet-mediated damage leaves normal clotting untouched, avoiding unwanted side effects.

Despite the promising lab results, no clinical trials for L-aspartate in MASLD or MASH patients have been registered as of February 2026. The compound remains widely available and is considered safe, raising the possibility of future nutritional therapies for fatty liver disease.

The study presents a clear mechanism by which L-aspartate could protect and restore liver function in metabolic diseases. Its ability to act without disrupting essential platelet activity marks it as a potential precision treatment. While human trials are still needed, the findings open a path for simple, diet-based interventions against a growing global health issue.